-
由國家新藥篩選中心主辦的 2016年皇后鎮(zhèn)分子生物學(xué)(上海)會(huì)議于2016-03-17在中國金融信息中心舉辦。
首頁>演講嘉賓> Fang Fang更新時(shí)間:2016-03-17
Fang Fang,CEO of Abimmune Biopharma, Inc., San Diego, U.S.A. She received close to $100M government grants; brought a first-in-class drug (Fludase) from a pure concept to saving over 100 lives (including infants) under the FDA emergency use authorization; received "Scientific American 50" Award. After close to 10 clinical trials, Fludase was granted “Breakthrough and Fast Track” status by the FDA for the indication of Para-Influenza for which no drug or vaccine is available.于2016年3月17-18日受邀參加了2016年皇后鎮(zhèn)分子生物學(xué)(上海)會(huì)議,并以"From a pure concept to a first-in-class live saving drug and more”為題目,發(fā)表了精彩的演講。
Fang Fang出席會(huì)議日程
由國家新藥篩選中心主辦的 2016年皇后鎮(zhèn)分子生物學(xué)(上海)會(huì)議于2016-03-17在中國金融信息中心舉辦。